MHC-I genotype and tumor mutational burden predict response to immunotherapy

ConclusionsPoor presentation of driver mutation neoantigens by MHC-I may explain why some tumors (even with a high TMB) do not respond to ICB.
Source: Genome Medicine - Category: Genetics & Stem Cells Source Type: research